Shares Outstanding (Quarterly) Chart

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 116.69M
March 31, 2026 116.27M
December 31, 2025 115.36M
September 30, 2025 115.34M
June 30, 2025 114.66M
March 31, 2025 114.60M
December 31, 2024 113.93M
September 30, 2024 113.88M
June 30, 2024 113.85M
March 31, 2024 113.80M
December 31, 2023 98.63M
September 30, 2023 98.59M
June 30, 2023 98.52M
March 31, 2023 98.19M
December 31, 2022 97.29M
September 30, 2022 97.11M
June 30, 2022 96.86M
March 31, 2022 96.54M
December 31, 2021 95.73M
September 30, 2021 95.36M
June 30, 2021 94.27M
March 31, 2021 93.89M
December 31, 2020 87.72M
September 30, 2020 87.00M
June 30, 2020 86.80M
Date Value
March 31, 2020 76.00M
December 31, 2019 75.73M
September 30, 2019 75.42M
June 30, 2019 65.31M
March 31, 2019 65.12M
December 31, 2018 64.69M
September 30, 2018 64.50M
June 30, 2018 53.39M
March 31, 2018 52.86M
December 31, 2017 52.65M
September 30, 2017 41.46M
June 30, 2017 41.42M
March 31, 2017 41.40M
December 31, 2016 41.39M
September 30, 2016 34.15M
June 30, 2016 28.88M
March 31, 2016 28.86M
December 31, 2015 28.72M
September 30, 2015 28.72M
June 30, 2015 28.62M
March 31, 2015 20.64M
December 31, 2014 20.57M
September 30, 2014 20.56M
June 30, 2014 20.56M
March 31, 2014 20.46M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
AVITA Medical, Inc. 30.93M
Agenus, Inc. 42.62M
Amgen, Inc. 540.60M
Anika Therapeutics, Inc. 13.38M
BioCryst Pharmaceuticals, Inc. 255.26M